Myocarditis Appears Rare After COVID-19 Vaccination

Clinicians should consider age, sex, and vaccine type when accounting for vaccination risks, according to the authors of an observational study.

Related Keywords

Tennessee ,United States ,Canada ,United Kingdom ,Vanderbilt University ,Vancouver ,British Columbia ,British ,Canadian ,Naveed Janjua ,Centers For Disease ,Vanderbilt Vaccine Research Program ,National Institutes Of Health ,Medscape Coronavirus Resource Center ,Canadian Immunization Research Network ,British Columbia Centre For Disease ,Canadian Institutes Of Health Research ,Pfizer ,Immunity Task ,Public Health Agency Of Canada ,Vanderbilt University School Of Medicine ,Vaccine Surveillance Reference Group ,Canadian Medical Association Journal ,Coronavirus Resource ,British Columbia Centre ,Disease Control ,Medscape Medical ,Canadian Medical Association ,Vanderbilt University School ,National Institutes ,Public Health Agency ,Canadian Institutes ,Health Research ,Covid 19 Vaccine ,Coronavirus Vaccine ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Myocarditis ,Cardiomyopathy ,Vaccine ,Immunizations ,Vaccination ,Patient Safety ,Hospitals , ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Diarrhea ,Adverse Effects ,